10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
10x Genomics, Inc. reported the results of its 2026 annual meeting of stockholders held via live webcast on June 4, 2026. Stockholders representing 198,815,518 votes, or approximately 90.5% of the 219,700,782 eligible votes, were present in person or by proxy, constituting a quorum.
Three Class I directors were elected to three-year terms expiring at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes represented at meeting: 198,815,518 votes
Votes for Serge Saxonov: 164,137,381 votes
Auditor ratification votes for EY: 197,719,939 votes
+1 more
4 metrics
Votes represented at meeting
198,815,518 votes
Approximately 90.5% of 219,700,782 eligible votes at June 4, 2026 annual meeting
Votes for Serge Saxonov
164,137,381 votes
Election as Class I director at 2026 annual meeting
Auditor ratification votes for EY
197,719,939 votes
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Say-on-pay votes for
176,677,540 votes
Non-binding advisory approval of named executive officer compensation
Key Terms
broker non-votes, independent registered public accounting firm, non-binding, advisory basis, quorum
4 terms
broker non-votes financial
"Nominee | Votes For | Votes Against | Abstentions | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding, advisory basis financial
"approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
quorum financial
"219,700,782 eligible votes, constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(925 ) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 4, 2026 via live webcast (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 117,542,161 shares of the Company's Class A and Class B common stock, representing 198,815,518, or approximately 90.5%, of the 219,700,782 eligible votes, constituting a quorum. The matters submitted to a vote at the Annual Meeting and the final voting results of such matters were as follows:
Proposal 1 - Election of Directors
The Company’s stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or until his earlier resignation or removal. The final voting results were as follows:
| Nominee | Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||||||||||||||||
| Serge Saxonov | 164,137,381 | 15,559,860 | 557,329 | 18,560,948 | ||||||||||||||||||||||
| Benjamin J. Hindson | 162,942,766 | 16,761,532 | 550,270 | 18,560,950 | ||||||||||||||||||||||
| John R. Stuelpnagel | 155,628,365 | 24,072,179 | 554,023 | 18,560,951 | ||||||||||||||||||||||
Proposal 2 - Ratification of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. There were no broker non-votes on this proposal. The final voting results were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 197,719,939 | 458,231 | 637,346 | — | |||||||||||||||||
Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers
The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026. The final voting results were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 176,677,540 | 2,828,730 | 748,296 | 18,560,952 | |||||||||||||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc. | ||||||||
By: | /s/ Randy Wu | |||||||
Name: | Randy Wu | |||||||
Title: | General Counsel and Secretary | |||||||
| Date: June 8, 2026 | ||||||||
FAQ
How many votes were represented at the 10x Genomics (TXG) 2026 annual meeting?
The meeting had 198,815,518 votes represented, or about 90.5% of 219,700,782 eligible votes. This level of participation meant a quorum was present, allowing all proposals on the agenda to be properly considered and voted on.
Were 10x Genomics (TXG) director nominees elected at the 2026 annual meeting?
Yes. All three Class I director nominees were elected. Serge Saxonov received 164,137,381 votes for, Benjamin J. Hindson received 162,942,766 votes for, and John R. Stuelpnagel received 155,628,365 votes for, each with additional votes against, abstentions, and broker non-votes recorded.